Medical/Pharmaceuticals News & Press Release Distribution

Inteleos Announces Maya Health Alliance as MissionPOCUS Selection for 2022

ROCKVILLE, Md., June 9, 2022 /PRNewswire/ -- Today Inteleos announced a pilot project withWuqu' Kawoq | the Maya Health Alliance as the selection of the Point-of-Care Ultrasound (POCUS) Certification Academy's 2022 MissionPOCUS™ project. As the fifth MissionPOCUS project since the initiative's in...

2022-06-09 22:17 4455

Inteleos Announces Maya Health Alliance as MissionPOCUS Selection for 2022

ROCKVILLE, Md., June 9, 2022 /PRNewswire/ -- Today Inteleos announced a pilot project withWuqu' Kawoq | the Maya Health Alliance as the selection of the Point-of-Care Ultrasound (POCUS) Certification Academy's 2022 MissionPOCUS™ project. As the fifth MissionPOCUS project since the initiative's in...

2022-06-09 22:09 2113

BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention

BOSTON, June 9, 2022 /PRNewswire/ -- BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation onJune 16, 12:00 at BIO International convention, taking place inSan Diego, California, between June 13-16, 2022. BIORCEHSTRA's company presentation will cover its lead therapeut...

2022-06-09 20:30 1876

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 2574

Nippon Express Launches Ultra-low Temperature-controlled Logistics Service for Pharmaceutical Industry

TOKYO, June 9, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of Nippon Express Holdings, Inc., launched on May 30 a logistics service capable of handling goods requiring ultra-low temperatures (-20 C to -85 C) for the pharmaceutical industry. Logo: ...

2022-06-09 15:00 2228

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

- Merck's retrosynthesis AI software 'SYNTHIA™ retrosynthesis software' accelerates Standigm's synthesis capability SEOUL, South Korea, June 9, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing o...

2022-06-09 14:46 1470

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022

HANGZHOU, China and SAN FRANCISCO, June 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that two abstracts have been accepted for poster presen...

2022-06-09 08:00 2059

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the onl...

2022-06-09 00:56 3215

Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board

Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 8, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in cancer, is progressing towards clinical trials following a ...

2022-06-09 00:05 1867

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval inthe United States and the European Union PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ -- Today, Medison Pharma ("Medison"), a g...

2022-06-08 23:54 2370

Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

-- ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials inChina, the U.S. and European Union -- Gannex expects to complete this DDI study at the beginning ...

2022-06-08 20:10 2237

UTSA awards $4 million to Oskar Fischer Prize recipients for innovative explanations of Alzheimer's disease

SAN ANTONIO, June 8, 2022 /PRNewswire/ -- The University of Texas at San Antonio (UTSA) today announced the 10 recipients of the Oskar Fischer Prize, an international competition to expand society's understanding of the causes of Alzheimer's disease. The prize, the world's largest of its kind, to...

2022-06-08 20:05 1706

OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate

NEW YORK, June 8, 2022 /PRNewswire/ -- OnCusp Therapeutics announced today a licensing agreement with Multitude Therapeutics for the development and commercialization of AMT-707 (now referred to as CUSP06), a potentially highly differentiated second-in-class CDH6 antibody drug conjugate ("ADC"). ...

2022-06-08 20:00 1588

Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 8, 2022 /PRNewswire/ --Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved the investigational new drug (IND) application to commence phase I trial of its B7H4x4-...

2022-06-08 18:11 1398

Dr Aaron Poh shares Advanced Surgical Techniques for Colorectal Cancer, the Top 3 Most Common Cancer Worldwide

SINGAPORE, June 8, 2022 /PRNewswire/ -- Dr Aaron Poh shares advanced surgical techniques for Colorectal Cancer. Full text is as follows: Dr Aaron Poh shares Advanced Surgical Tech...

2022-06-08 10:00 2035

Dr Aaron Poh shares Advanced Surgical Techniques for Colorectal Cancer, the Top 3 Most Common Cancer Worldwide

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...

2022-06-08 09:23 2357

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-06-08 08:30 1874

ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

SUZHOU, China, and ROCKVILLE, MD, June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the results from its Phase I ...

2022-06-08 08:00 1357

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated results from a Pha...

2022-06-08 08:00 1439

First Patient Enrolled in SELUTION SLR IDE BTK Study

LEIPZIG, Germany, June 8, 2022 /PRNewswire/ -- The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just one week after receiving IDE approval.

2022-06-08 08:00 2166